ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,667.20
0.64%
Dow Jones
40,954.48
1.85%
US Dollar vs MXN
17.64101
-0.51%
Brent Oil
83.235
-1.31%
Bitcoin
65,067.48
0.33%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Compugen Ltd (CGEN)

  7. Compugen Ltd (CGEN) Noticias

CGEN

Compugen (CGEN)

Compugen Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CGEN
FechaHoraFuenteTítuloSímboloCompañía
26/02/202406:00PR Newswire (US)Compugen to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:CGENCompugen Ltd
20/02/202406:00PR Newswire (US)Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024NASDAQ:CGENCompugen Ltd
15/02/202406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
15/02/202406:00PR Newswire (US)Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical OfficerNASDAQ:CGENCompugen Ltd
08/01/202406:05PR Newswire (US)Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerNASDAQ:CGENCompugen Ltd
08/01/202406:00PR Newswire (US)Compugen Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CGENCompugen Ltd
19/12/202308:30AllPennyStocks.comStrong Open For Biotech Following Exclusive Agreement AnnouncementNASDAQ:CGENCompugen Ltd
19/12/202306:10PR Newswire (US)Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerNASDAQ:CGENCompugen Ltd
19/12/202306:05PR Newswire (US)Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 BiologyNASDAQ:CGENCompugen Ltd
19/12/202306:00Business WireGilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy ProgramNASDAQ:CGENCompugen Ltd
07/11/202306:00PR Newswire (US)Compugen Reports Third Quarter 2023 ResultsNASDAQ:CGENCompugen Ltd
06/11/202306:00PR Newswire (US)Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to ImmunotherapyNASDAQ:CGENCompugen Ltd
03/11/202315:35PR Newswire (US)Compugen Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:CGENCompugen Ltd
31/10/202308:00PR Newswire (US)Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating CancerNASDAQ:CGENCompugen Ltd
24/10/202306:00PR Newswire (US)Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023NASDAQ:CGENCompugen Ltd
03/10/202306:00PR Newswire (US)Compugen to Present at Single Cell Genomics 2023 MeetingNASDAQ:CGENCompugen Ltd
02/10/202306:00PR Newswire (US)Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of CancerNASDAQ:CGENCompugen Ltd
27/09/202308:00PR Newswire (US)Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023NASDAQ:CGENCompugen Ltd
31/08/202306:00PR Newswire (US)Compugen to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CGENCompugen Ltd
23/08/202307:00Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:CGENCompugen Ltd
07/08/202306:00PR Newswire (US)Compugen Reports Second Quarter 2023 ResultsNASDAQ:CGENCompugen Ltd
24/07/202306:00PR Newswire (US)Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023NASDAQ:CGENCompugen Ltd
17/07/202306:00PR Newswire (US)Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third PartyNASDAQ:CGENCompugen Ltd
23/06/202315:17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:CGENCompugen Ltd
22/06/202306:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CGENCompugen Ltd
22/06/202306:00PR Newswire (US)Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept StudyNASDAQ:CGENCompugen Ltd
05/06/202306:00PR Newswire (US)Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial CancerNASDAQ:CGENCompugen Ltd
15/05/202306:00PR Newswire (US)Compugen Reports First Quarter 2023 ResultsNASDAQ:CGENCompugen Ltd
11/05/202306:00PR Newswire (US)Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023NASDAQ:CGENCompugen Ltd
09/05/202306:00PR Newswire (US)Compugen to Present at the JMP Securities Life Sciences ConferenceNASDAQ:CGENCompugen Ltd
 Showing the most relevant articles for your search:NASDAQ:CGEN

Su Consulta Reciente

BOV
FSPM11
F3 Fundshares Portfolio ...
LSE
CBU3
Ishr $ Gov 1-3a
NASDAQ
DAGXX
Dreyfus Govt Cash Administrative
LSE
NETW
Network
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados